Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO37EF
|
|||
| Drug Name |
CY6463
|
|||
| Synonyms |
Zagociguat; Zagociguat [INN]; H7KEN3O8AI; UNII-H7KEN3O8AI; 2201048-82-8; CY6463; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; ZAGOCIGUAT [USAN]; SCHEMBL19922804; GTKNNCQKFKGSHR-UHFFFAOYSA-N; EX-A7620; AKOS040757400; CY-6463; IW-6463; MS-25746; HY-145607; CS-0376702; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Cyclerion therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H10F4N6
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)CC2=NC(=CN3C2=NC=C3)C4=NNC(=N4)C(F)(F)F)F
|
|||
| InChI |
InChI=1S/C16H10F4N6/c17-10-4-2-1-3-9(10)7-11-14-21-5-6-26(14)8-12(22-11)13-23-15(25-24-13)16(18,19)20/h1-6,8H,7H2,(H,23,24,25)
|
|||
| InChIKey |
GTKNNCQKFKGSHR-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Soluble guanylate cyclase (GCS) | Target Info | Stimulator | [2] |
| Soluble guanylate cyclase (GCS) | Target Info | Modulator | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04798989) A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology. U.S.National Institutes of Health. | |||
| REF 2 | First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395. | |||
| REF 3 | Clinical pipeline report, company report or official report of Cyclerion Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.